Gilead Sciences operates at significant scale in the pharmaceuticals sector, with an Impact500 score of 77.3 and a C grade in the current modeled research cycle. Its strongest modeled pillar is ethics, while future research will continue to test disclosure quality, implementation evidence, and outcomes against sector peers. For companies in this industry, access, affordability, patient safety, workforce resilience, product stewardship, and ethical innovation are central responsibility issues. The opportunities identified in this report are forward-looking practices, not findings of misconduct or evidence that a program is absent. Structural facts retain their source year, and readers should consult the evidence and document sections before using the profile for decisions.
Company overview
Business context and responsibility.
Gilead Sciences is a large pharmaceuticals organization headquartered in Foster City, CA. Founded in 1987, the company has developed through multiple business and market cycles into an enterprise serving patients, providers, employers, governments, and health systems. The organization reports approximately 9,000 employees and $29.4 billion in annual revenue in the structural dataset used for this profile. Its Fortune rank of 153 is retained with the published 2026 source year and should not be read as a current ranking. Its competitive position is supported by specialized expertise, regulated operations, broad distribution, and the capacity to improve health outcomes. Operations of this scale typically span multiple regions, customer groups, suppliers, and regulatory environments, making consistent governance and performance measurement central to long-term strategy. From a corporate-responsibility perspective, the most material research questions concern access, affordability, patient safety, workforce resilience, product stewardship, and ethical innovation. Impact500 evaluates the company through environmental performance, financial responsibility, philanthropy, and ethics. The profile therefore emphasizes comparable disclosure, evidence of implementation, board and executive accountability, and year-over-year outcomes. Company-specific assertions remain linked to cited evidence; modeled indicators and sector-based research guidance are labeled separately until analyst verification is complete.
Executive leadership
Daniel P. O'Day
Chief Executive Officer
Appointment year pending verification
Daniel P. O'Day currently leads Gilead Sciences. Impact Horizon last checked this leadership record on 2026-08-22.
Fortune rank and leadership are displayed with their source year and latest review date. Expanded profiles may retain historical structural facts and modeled Impact Horizon responsibility values pending analyst review.
The published pharmaceuticals cohort contains 13 companies with an average CSR score of 72.4. Comparisons emphasize disclosure quality, verified outcomes, and sector-specific operating risks.
Competitive position
Ranked #3 in its published peer group.
Gilead Sciences scores 4.9 points above its industry average and changed +1% in the latest cycle.
Industry benchmarks
Performance against published peers.
Environmental
79 vs 71.1
Philanthropy
71 vs 68.6
Ethics
81 vs 74.2
Financial responsibility
78 vs 75.5
White markers show the published industry average.
Opportunities for improvement
Forward-looking priorities.
These recommendations reflect sector best practices and research priorities. They are constructive opportunities, not claims that a program is absent or that current performance is deficient.
1
Report clearer access, affordability, quality, and patient-outcome measures across major products and services.
2
Strengthen responsible sourcing and environmental targets for facilities, products, packaging, and logistics.
3
Expand workforce well-being, clinical talent, and community-health investments with measurable outcomes.
4
Publish transparent governance standards for patient data, research ethics, and emerging technologies.
Strengths
Clear targets, consistently disclosed performance, and accountable executive ownership.
Watch areas
Continued reporting depth and independent validation remain material to future scores.
Industry context
72.4
Pharmaceuticals average
Above sector average by 4.9 points
Key strengths
Published responsibility disclosures
Established enterprise governance
Sector-scale health care operations
Watch areas
Outcome evidence requires continued review
Modeled score pending source-level verification
Historical timeline
Score history and CSR milestones.
202172.3
Baseline research cycle established.
202273.3
+1.0 points from prior cycle.
202374.4
+1.1 points from prior cycle.
202474.7
+0.3 points from prior cycle.
202575.8
+1.1 points from prior cycle.
202676.8
+1.0 points from prior cycle.
CSR initiatives
Programs under review.
Insufficient public information available.
Impact Horizon analysis
Risk Analysis
Sector-relevant exposures for Gilead Sciences, interpreted against the current peer data. Inclusion is not evidence that an adverse event occurred and does not change the CSR score.
Risk profile: Elevated Risk
Analyst observation
Analyst Observations
Research-based interpretation of the current Impact Horizon dataset. These observations are analytical judgments, not company-reported facts.
AO-01
Major strength
Ethics is the strongest current pillar at 81.0. This is a comparative signal from the Impact Horizon dataset, not an external assurance opinion.
AO-02
Important gap
Philanthropy is the lowest current pillar at 71.0 and is the clearest area for deeper source review.
AO-03
Trend
The latest published research cycle moved +1.0 points. The change describes the dataset and does not by itself establish causation.
AO-04
Industry context
Gilead Sciences ranks 3 of 13 Pharmaceuticals companies and scores 4.9 points above the peer average.
AO-05
Area to monitor
Regulatory Risk is the leading sector-relevant watch area in this profile. Its inclusion identifies research exposure, not a finding of misconduct.
AO-06
Potential opportunity
Report clearer access, affordability, quality, and patient-outcome measures across major products and services.